CVS has won antitrust approval to purchase Caremark Rx, the pharmacy benefit manager, removing potential regulatory opposition to the pending $21 billion acquisition. The approval by the Federal Trade Commission comes shortly after Express Scripts launched rival $26 billion bid for Caremark in hopes of wresting its rival away from CVS. Should either CVS or Caremark scuttle the deal because of a competing offer, it would pay the other a breakup fee of $675 million, CVS’s chief financial officer, David B. Rickard, said in an interview last month.
Go to Article from Bloomberg News via The New York Times »
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment